Company / R&D per Share
AbbVie R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$5.13
FY2025
5-year range
$3.89 / $7.19
FY2021-FY2025
Trend
-28.7%
vs FY2024
Sector context
#32 of 207
Health Care
What the data says
AbbVie's r&d per share of $5.13 is higher than 85% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $2.72 in FY2016 to $7.19 in FY2024.
Based on SEC 10-K filings.
5.13 in FY2025 with a 5-year CAGR of +4.5%. Top quartile in the Health Care sector.
Improved from $4.32 to $5.13 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +9.7%
- 5-Year CAGR
- +4.5%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 207This company $5.13 Sector average $12.26
▼
-58.1% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 28.7% year-over-year.
- Ranks #32 out of 207 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.13 | -28.7% |
| FY2024 | $7.19 | +66.6% |
| FY2023 | $4.32 | +11.0% |
| FY2022 | $3.89 | -16.6% |
| FY2021 | $4.66 | +13.0% |
| FY2020 | $4.13 | +3.2% |
| FY2019 | $4.00 | -36.9% |
| FY2018 | $6.33 | +107.1% |
| FY2017 | $3.06 | +12.3% |
| FY2016 | $2.72 | +2.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026